Relationship between serum interleukin-31/25-hydroxyvitamin D levels and the severity of atopic dermatitis in children

Yang, Yun Seok; Lee, Jung Won; Shim, Jae Won; Kim, Deok Soo; Jung, Hye Lim; Park, Moon Soo; Shim, Jung Yeon

doi:10.4168/aard.2015.3.6.396

Original Article

Open Access


Allergy Asthma Respir Dis. 2015 Nov;3(6):396-401. Korean. Published online November 30, 2015. https://doi.org/10.4168/aard.2015.3.6.396
© 2015 The Korean Academy of Pediatric Allergy and Respiratory Disease; The Korean Academy of Asthma, Allergy and Clinical Immunology


Relationship between serum interleukin-31/25-hydroxyvitamin D levels and the severity of atopic dermatitis in children
Yun Seok Yang, Jung Won Lee, Jae Won Shim, Deok Soo Kim, Hye Lim Jung, Moon Soo Park and Jung Yeon Shim
Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Correspondence to: Jung Yeon Shim. Division of Pediatric Allergy & Pulmonology, Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 04516, Korea. Tel: +82-2-2001-2484, Fax: +82-2-2001-2199, Email: jy7.shim@samsung.com

Received June 08, 2015; Revised July 28, 2015; Accepted August 13, 2015.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).
This article has been cited by 1 article in KoMCI. This article has been cited by Google Scholar.
Go to: Abstract
Purpose Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease. Vitamin D and interleukin-31 (IL-31) are known to be related to the pathogenesis of AD with pruritus. The purpose of this study was to investigate the relationship between serum levels of 25-hydroxyvitamin D (25(OH)D) and IL-31 and the disease severity of AD in children with AD. Methods We recruited 160 children with AD and 42 controls. We used the SCORing Atopic Dermatitis (SCORAD) index to measure the severity of AD. Serum IL-31 and 25(OH)D levels were assayed using enzyme-linked immunosorbent assay and high-performance liquid chromatography, respectively. Serum levels of total IgE, specific IgE to common allergens and peripheral blood total eosinophil count were carried out in children with AD. Results Serum IL-31 level was significantly higher in AD group compared to control group and 25(OH)D level was significantly lower in AD group than control group. Serum IL-31 level showed the highest level in severe AD group followed by moderate and mild AD group, whilst serum 25(OH)D level was the lowest in severe AD group compared to moderate and mild AD group. There was no difference in serum IL-31 level between AD group and nonatopic dermatitis group. IL-31 level was positively correlated with subjective SCORAD index indicating pruritus in children with AD, and 25(OH)D was inversely correlated with SCORAD index. Conclusion IL-31 and vitamin D may be related to the pathogenesis of AD, especially with regard to the pruritus.


Keywords: Atopic dermatitis; Interleukin-31; 25-hydroxyvitamin D; Pediatrics

Go to:

Figures


	Fig. 1 Serum levels of 25(OH)D and IL-31 in children with atopic dermatitis and control group. (A) Serum IL-31 level was significantly higher in AD group compared to control group and (B) 25(OH)D level was significantly lower in AD group compared to control group. 25(OH)D, 25-hydroxyvitamin D; IL, interleukin; AD, atopic dermatitis.
	Click for larger imageDownload as PowerPoint slide


	Fig. 2 Correlation between the SCORAD index, subjective SCORAD index, serum levels of 25(OH)D, and IL-31. The levels of IL-31 showed a positive correlation with the SCORAD index (A), and subjective SCORAD index (B). The levels of 25(OH)D were inversely correlated with the SCORAD index (C), and subjective SCORAD index (D). (E) The levels of 25(OH)D were inversely correlated with the IL-31 concentration. SCORAD, SCORing Atopic Dermatitis; 25(OH)D, 25-hydroxyvitamin D; IL, interleukin.
	Click for larger imageDownload as PowerPoint slide

Go to:

Tables


	Table 1 Clinical and laboratory characteristics of study subject
	Click for larger imageClick for full tableDownload as Excel file


	Table 2 Comparison of IL-31, 25(OH)D, total IgE, and blood eosinophil count by severity of atopic dermatitis
	Click for larger imageClick for full tableDownload as Excel file


	Table 3 Comparison of IL-31, 25(OH)D, total IgE, and blood eosinophil count in children with atopic dermatitis by atopic sensitization
	Click for larger imageClick for full tableDownload as Excel file

Go to:

References


1.	Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733–743.

2.	Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002;11:12–24.

3.	Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–281.

4.	Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009;94:26–34.

5.	Grober U, Spitz J, Reichrath J, Kisters K, Holick MF. Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcare. Dermatoendocrinol 2013;5:331–347.

6.	Bonanno A, Gangemi S, La Grutta S, Malizia V, Riccobono L, Colombo P, et al. 25-Hydroxyvitamin D, IL-31, and IL-33 in children with allergic disease of the airways. Mediators Inflamm 2014;2014:520241.

7.	Baumann R, Rabaszowski M, Stenin I, Gaertner-Akerboom M, Scheckenbach K, Wiltfang J, et al. The release of IL-31 and IL-13 after nasal allergen challenge and their relation to nasal symptoms. Clin Transl Allergy 2012;2:13.

8.	Wittke A, Weaver V, Mahon BD, August A, Cantorna MT. Vitamin D receptor-deficient mice fail to develop experimental allergic asthma. J Immunol 2004;173:3432–3436.

9.	Chiu YE, Havens PL, Siegel DH, Ali O, Wang T, Holland KE, et al. Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severity. J Am Acad Dermatol 2013;69:40–46.

*10.*	Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev 2008;19:347–356.

*11.*	Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004;5:752–760.

*12.*	Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:44–47.

*13.*	Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23–31.

*14.*	Takaoka A, Arai I, Sugimoto M, Honma Y, Futaki N, Nakamura A, et al. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol 2006;15:161–167.

*15.*	Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117:411–417.

*16.*	Kim S, Kim HJ, Yang HS, Kim E, Huh IS, Yang JM. IL-31 serum protein and tissue mRNA levels in patients with atopic dermatitis. Ann Dermatol 2011;23:468–473.

*17.*	Raap U, Weibmantel S, Gehring M, Eisenberg AM, Kapp A, Folster-Holst R. IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis. Pediatr Allergy Immunol 2012;23:285–288.

*18.*	Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol 2011;25:334–339.

*19.*	Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441–446.

*20.*	Hata TR, Kotol P, Jackson M, Nguyen M, Paik A, Udall D, et al. Administration of oral vitamin D induces cathelicidin production in atopic individuals. J Allergy Clin Immunol 2008;122:829–831.

*21.*	Samochocki Z, Bogaczewicz J, Jeziorkowska R, Sysa-Jedrzejowska A, Glinska O, Karczmarewicz E, et al. Vitamin D effects in atopic dermatitis. J Am Acad Dermatol 2013;69:238–244.

*22.*	Camargo CA Jr, Ganmaa D, Sidbury R, Erdenedelger Kh, Radnaakhand N, Khandsuren B. Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. J Allergy Clin Immunol 2014;134:831–835.e1.

*23.*	Amestejani M, Salehi BS, Vasigh M, Sobhkhiz A, Karami M, Alinia H, et al. Vitamin D supplementation in the treatment of atopic dermatitis: a clinical trial study. J Drugs Dermatol 2012;11:327–330.

*24.*	Pichler J, Gerstmayr M, Szepfalusi Z, Urbanek R, Peterlik M, Willheim M. 1 alpha,25(OH)2D3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Pediatr Res 2002;52:12–18.

*25.*	Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001;167:4974–4980.

*26.*	Jirapongsananuruk O, Melamed I, Leung DY. Additive immunosuppressive effects of 1,25-dihydroxyvitamin D3 and corticosteroids on TH1, but not TH2, responses. J Allergy Clin Immunol 2000;106:981–985.

*27.*	Staeva-Vieira TP, Freedman LP. 1,25-dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J Immunol 2002;168:1181–1189.

*28.*	Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995;125 6 Suppl:1704S–1708S.

*29.*	Hypponen E, Berry DJ, Wjst M, Power C. Serum 25-hydroxyvitamin D and IgE: a significant but nonlinear relationship. Allergy 2009;64:613–620.

*30.*	Cheon BR, Shin JE, Kim YJ, Shim JW, Kim DS, Jung HL, et al. Relationship between serum 25-hydroxyvitamin D and interleukin-31 levels, and the severity of atopic dermatitis in children. Korean J Pediatr 2015;58:96–101.